12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Tango Therapeutics (NASDAQ:TNGX) stock increased by 58.7% to $6.08 during Tuesday’s after-market session. At the close, Tango…
BioLife Solutions Sees FY23 Revenue $144M-$158M Vs $186.31M Est.
2023 Revenue Guidance
BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business.
Total revenue for 2023 is expected to range from $144
Benzinga’s Top Ratings Upgrades, Downgrades For July 11, 2023
Upgrades For Generac Holdings Inc (NYSE:GNRC), Argus Research upgraded the previous rating of Hold to Buy. For the…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Ampio Pharmaceuticals (AMEX:AMPE) stock increased by 38.6% to $0.28 during Wednesday’s after-market session. Today’s trading volume for…
BioLife Solns: Q1 Earnings Insights
BioLife Solns (NASDAQ:BLFS) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:00 PM. Here’s what…
Earnings Scheduled For May 10, 2023
Companies Reporting Before The Bell
• Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.
BioLife Solutions Q4 Sales $44.26M Beat $43.28M Estimate
BioLife Solutions (NASDAQ:BLFS) reported quarterly sales of $44.26 million which beat the analyst consensus estimate of $43.28 million by 2.26 percent. This is a 18.64 percent increase over sales of $37.30 million the
Oppenheimer Reiterates Outperform on BioLife Solns, Maintains $28 Price Target
Oppenheimer analyst Suraj Kalia reiterates BioLife Solns (NASDAQ:BLFS) with a Outperform and maintains $28 price target.
BioLife Solutions Expands Intellectual Property Estate
7 New Granted Patents; 43 Submitted Patent Applications
Global Portfolio Now Totals 148 Issued and 114 Pending Patents
BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a
